This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drugdevelopment and diagnostics. Across its funds, HTGF has over 2 billion euros under management.
Steve Case, the billionaire founder of America OnLine (AOL) launched a company called Revolution Health Group in 2005. This is due to a multitude of factors, but administrative and marketing costs are a large component of this higher drug pricing. Cost Plus Drug Company seeks to lower the cost of popular medications for US consumers.
Understanding and Development (1990s-2000s): 1990s: Research delves into the GLP-1 receptor and its role in regulating metabolism. 2005: Liraglutide, another GLP-1 RA, joins the scene, offering longer-lasting action. 1996: Studies suggest GLP-1's potential in managing type 2 diabetes and obesity.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
77 
Let's personalize your content